David Hutton

The MERIT study found that intraocular corticosteroid treatment remains the most effective therapy for uveitis-related macular edema, and vision gains in participants who received the corticosteroid treatment were very promising.

Eyebiotech noted its AMARONE trial will evaluate the safety and preliminary efficacy of intravitreal EYE103.

Results of the Alcon Eye on Cataract Survey highlight misconceptions about cataract surgery, revealing the need to educate the 50+ population on the procedure and treatment options.

Researchers are involved in the development of Eye2Gene, an AI system capable of identifying the genetic cause of IRDs from retinal scans.

A vitreoretinal surgeon, Hariprasad joined the University of Chicago in 2005, and has been serving as interim chairman since 2020.

Scientists hope to develop of novel AI solutions for the prediction of DPN using corneal OCT images.

According to the company, CyclASol is preservative-free and does not contain any oils or surfactants, which can be irritating and disturbing for the tear film.

The Texas Medical Board suspends the license of David Stager Jr, MD, FACS, FAAP, a year after he had complied with a previous disciplinary action.

According to researchers, lesions in women’s eyes were significantly more likely to occur in the central retina compared with those in men’s eyes.

An inexpensive laser could increase access to OCT imaging, helping to catch eye problems early.

For Michael A. Puente Jr., MD, being open about himself and advocating for an overlooked community hasn’t always been as easy as it is today. Progress has been incremental, but he is optimistic about the state of ophthalmology for LGBTQ+ physicians and patients.

The event is a forum for the exchange of ideas between leading scientists in diverse fields to bring their knowledge to the challenges of glaucoma and help set the course for future glaucoma research.

According to the company, topline results from the clinical trial are expected by the third quarter of 2024.

According to the company, the Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with USH, with interim efficacy data anticipated by the end of the year.

According to the company, CTx-PDE6b in patients with retinitis pigmentosa caused by bi-allelic mutations in PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile.

The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities, such as transgender women or nonbinary donors, will be impacted.

According to company officials,the new image modality provides additional retinal visualization to our customers as they manage their patient’s treatment and ongoing care.

According to the company, the Preservative Freedom Coalition will put the topic of preservative-free eye care in focus through education to eye care professionals and patients.

In a Wilmer Eye Institute study, in mice and human cell models, the drug 32-134D lowered protein levels known to contribute to diabetic macular edema and diabetic retinopathy

According to the company, its latest laser recently received FDA clearance and CE mark approval.

According to the company, THR-149 is currently being evaluated in the KALAHARI Phase 2, Part B clinical trial as a potential treatment for patients who respond suboptimally to anti-VEGF, the standard of care for treatment of DME.

The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.

According to the company, AG-73305 was found to be safe and tolerable with no severe adverse effects after a single intravitreal injection of 0.5 mg and 1 mg in patients diagnosed with diabetic macular edema.

According to the company, topical administration is capable of delivering metformin to choroid, RPE, and retina.

According to the company, the study has now reached its goal of 300 patients enrolled to evaluate ILUVIEN as a first line, baseline therapy for DME.

Instrumentation recreates properties of the myopic eye to test lenses that prevent visual decline.

According to the company, study results show sustained reductions in both IOP and glaucoma medication use in mild-moderate primary open angle glaucoma patients treated with a procedure enabled with the OMNI Surgical System technology.

According to the company, the Phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial. Up to 24 subjects will receive a single periocular injection and will undergo monthly evaluation for up to 6 months to assess safety, tolerability, and efficacy measured by best corrected visual acuity.